A detailed history of Groupe La Francaise transactions in Merus N.V. stock. As of the latest transaction made, Groupe La Francaise holds 60,000 shares of MRUS stock, worth $5.76 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
60,000
Holding current value
$5.76 Million
% of portfolio
0.08%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025

BUY
$52.33 - $94.15 $3.14 Million - $5.65 Million
60,000 New
60,000 $5.65 Billion

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $4.4B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Groupe La Francaise Portfolio

Follow Groupe La Francaise and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Groupe La Francaise, based on Form 13F filings with the SEC.

News

Stay updated on Groupe La Francaise with notifications on news.